Patient info Open main menu

Memantine DR Reddys 20 mg film-coated tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
20 mg
Contains active substance:
ATC code:
Similar medicines:

Patient leaflet - Memantine DR Reddys 20 mg film-coated tablets

1. What Memantine hydrochloride is and what it is used for

recently taken or might take any other medicines.

In particular, Memantine hydrochloride may change the effects of the following medicines and their dose may need to be adjusted by your doctor:

  • amantadine, ketamine, dextromethorphan
  • dantrolene, baclofen
  • cimetidine, ranitidine, procainamide, quinidine,

    quinine, nicotine

  • hydrochlorothiazide (or any combination with

Memantine hydrochloride contains the active substance memantine hydrochloride. It belongs to a group of medicines known as anti-dementia medicines. Memory loss in Alzheimer’s disease is due to a disturbance of message signals in the brain. The brain contains so-called N-methyl-D-aspartate

(NMDA)-receptors that are involved in transmitting nerve signals important in learning and memory. Memantine hydrochloride belongs to a group of medicines called NMDA-receptor antagonists.

hydrochlorothiazide)

  • anticholinergics (substances generally used to treat

    movement disorders or intestinal cramps)

  • anticonvulsants (substances used to prevent and

    relieve seizures)

  • barbiturates (substances generally used to induce

    sleep)

  • dopaminergic agonists (substances such as

    L-dopa, bromocriptine)

  • neuroleptics (substances used in the treatment of

Memantine hydrochloride acts on these

NMDA-receptors improving the transmission of nerve signals and the memory.

Memantine hydrochloride is used for the treatment of patients with moderate to severe Alzheimer’s disease.

2. What you need to know before you take Memantine hydrochloride

Do not take Memantine hydrochloride

mental disorders)

  • oral anticoagulants.

If you go into hospital, let your doctor know that you are taking Memantine hydrochloride.

Memantine hydrochloride with food and drink

You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis

  • if you are allergic to memantine or any of the other

    ingredients of this medicine (listed in section 6). Warnings and precautions

Talk to your doctor or pharmacist before taking Memantine hydrochloride

  • if you have a history of epileptic seizures
  • if you have recently experienced a myocardial

    infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure).

    (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your doctor may need to adjust the dose of your medicine.

    Pregnancy and breast-feeding

    If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

In these situations the treatment should be carefully supervised, and the clinical benefit of Memantine hydrochloride reassessed by your doctor on a regular basis.

If you suffer from renal impairment (kidney problems), your doctor should closely monitor your kidney function and if necessary adapt the memantine hydrochloride doses accordingly.

Pregnancy

The use of memantine hydrochloride in pregnant women is not recommended.

Breast-feeding

Women taking Memantine hydrochloride should not breast-feed.

Driving and using machines

Your doctor will tell you whether your illness allows you

The use of medicinal products called amantadine (for the treatment of Parkinson’s disease), ketamine (a substance generally used as an anaesthetic), dextromethorphan (generally used to treat cough) and other NMDA-antagonists at the same time should be avoided.

Children and adolescents

Memantine hydrochloride is not recommended for children and adolescents under the age of 18 years.

to drive and to use machines safely. Also, Memantine hydrochloride may change your reactivity, making driving or operating machinery inappropriate.

3. How to take Memantine hydrochloride

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Dosage

The recommended dose of Memantine hydrochloride for adults and older people is 20 mg once a day. In order to

reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme:

The usual starting dose is half a tablet once a day (1 x 5 mg) for the first week. This is increased to one tablet once a day (1 x 10 mg) in the second week and to 1 and a half tablets once a day in the third week. From the fourth week on, the usual dose is 2 tablets once a day (1 x 20 mg).

Dosage in patients with impaired kidney function

If you have impaired kidney function, your doctor will decide upon a dose that suits your condition. In this

case, monitoring of your kidney function should be performed by your doctor at specified intervals. Administration

Memantine hydrochloride should be administered orally once a day. To benefit from your medicine you should take it regularly every day at the same time of the day. The tablets should be swallowed with some water. The tablets can be taken with or without food.

Duration of treatment

Continue to take Memantine hydrochloride as long as it is of benefit to you. Your doctor should assess your treatment on a regular basis.

If you take more Memantine hydrochloride than you should

  • In general, taking too much Memantine

    hydrochloride should not result in any harm to you. You may experience increased symptoms as described in section 4. “Possible side effects”.

  • If you take a large overdose of Memantine

    hydrochloride, contact your doctor or get medical advice, as you may need medical attention. If you forget to take Memantine hydrochloride

  • If you find you have forgotten to take your dose of

    Memantine hydrochloride, wait and take your next dose at the usual time.

  • Do not take a double dose to make up for a

    forgotten dose.

If you have any further questions on the use of this

medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

In general, the observed side effects are mild to moderate.

Common (may affect up to 1 in 10 people):

  • Headache, sleepiness, constipation, elevated liver

    function tests, dizziness, balance disorders, shortness of breath, high blood pressure and drug hypersensitivity

Uncommon (may affect up to 1 in 100 people):

  • Tiredness, fungal infections, confusion,

    hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting

    (thrombosis/thromboembolism)

Very Rare (may affect up to 1 in 10,000 people):

  • Seizures

    Not known (frequency cannot be estimated from the available data):

    • Inflammation of the pancreas, inflammation of the

      liver (hepatitis) and psychotic reactions

Alzheimer’s disease has been associated with depression, suicidal ideation and suicide. These events have been reported in patients treated with Memantine

hydrochloride.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at:

www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more in formation on the safety of this medicine.

week 1

week 2

week 3

week 4

and beyond

half a 10 mg tablet

one 10 mg tablet

one and a half 10 mg tablets

two 10 mg tablets once a day

5. How to store Memantine hydrochloride

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Memantine hydrochloride contains

The active substance is memantine hydrochloride. Memantine hydrochloride 10 mg film-coated tablets

contain 10 mg memantine hydrochloride equivalent to 8.31 mg memantine.

Memantine hydrochloride 20 mg film-coated tablets contain 20 mg memantine hydrochloride equivalent to 16.62 mg memantine.

The other ingredients are microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and magnesium stearate, povidone (K-30), all in the tablet core; and hypromellose, macrogol 400, titanium dioxide

(E171) and iron oxide yellow (E172) and red iron oxide (only in 20 mg film-coated tablet), all in the tablet coating.

What Memantine hydrochloride tablets look like and contents of the pack

Memantine hydrochloride 10 mg film-coated tablets are pale yellow to yellow, oval shaped film-coated tablets with breaking line and engravings “1 0” on one side and “R R” on the other side.

The tablet can be divided into equal doses.

Memantine hydrochloride 20 mg film-coated tablets are pale red to grey red, oval shaped film-coated tablets with breaking line and engravings “2 0” on one side and “R R” on the other side.

The tablet can be divided into equal doses.

Memantine hydrochloride film-coated tablets are available in blister packs of 7, 28, 42, 56, 98 and 112 tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Dr. Reddy’s Laboratories (UK) Ltd,

410 Cambridge Science Park, Milton Road, Cambridge, CB4 0PE, United Kingdom

This leaflet was last revised in 06/2022

PACKAGE LEAFLET: INFORMATION FOR THE USER Memantine hydrochloride 10 mg Film-Coated Tablets Memantine hydrochloride 20 mg Film-Coated Tablets

Memantine hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important

information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs

    of illness are the same as yours.

  • If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in

    this leaflet. See section 4.

    160 mm

    Please note that any low resolution paper Canon colour copies associated with this job should be referred to for content, layout and colour separation only.

    Submission

    Implementation Date: xx xxx xxxx Brand:

    Country:

    Product Name:

    Strength:

    Form:

    Pack Size:

    Date Created:

    Date Modified:

    160 x 300 mm Cambridge Project:

    DR Reddy’s

    UK

    Memantine Hydrochloride

    10 mg

    Film Coated Tablets

    Leaflet

    28s

    xx xxx xxx

    26 JUL 2022

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 08553/0498

Last revision stated in the text: June 2022 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Memantine DR Reddys 20 mg film-coated tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Memantine
Strength 20 mg
Pharmaceutical form Oral tablet
Pale red to grey red, oval shaped film-coated tablet with breaking line and engravings “2 0” on one side and “R R” on the other side. The tablet can be divided into equal doses.
How is it taken Oral
Excipients Microcrystalline cellulose, Croscarmellose sodium, Colloidal anhydrous silica, Povidone K 30, Magnesium stearate, Hypromellose, Macrogol 400, Titanium dioxide (E 171), Iron oxide yellow (E 172), Iron oxide red (E 172)
Pack sizes 28 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
Storage This medicinal product does not require any special storage conditions.
Drug group (ATC) Psychoanaleptics; Other Anti-dementia drugs
  1. N Nervous system drugs
    1. N06 Psychoanaleptics
      1. N06D Anti-dementia drugs
        1. N06DX Other anti-dementia drugs
          1. N06DX01 memantine
Marketing authorisation PL 08553/0498 (first authorised 22 May 2013)
Marketing authorisation holder Dr. Reddy’s Laboratories (UK) Ltd.
Codes GTIN 5036072005372 · BNF 04110000

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.